JNK抑制剂(BI-78D3) | 883065-90-5

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: JNK抑制剂(BI-78D3)
• 中文别名: 4-(2,3-二氢苯并[B][1,4]二恶英-6-基)-3-((5-硝基噻唑-2-基)硫基)-1H-1,2,4-三唑-5(4H)-酮；4-(2,3-二氢-1,4-苯并二恶英-6-基)-2,4-二氢-5-[(5-硝基-2-噻唑基)硫基]-3H-1,2,4-三唑-3-酮；4-(2,3-二氢-1,4-苯并二恶英-6-基)-2,4-二氢-5-[(5-硝基-2-噻唑基)硫基]-3H-1,2,4-三唑-3-一个
• 英文名称: 4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-3-((5-nitrothiazol-2-yl)thio)-1H-1,2,4-triazol-5(4H)-one
• 英文别名: 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1H-1,2,4-triazol-5-one
• CAS: 883065-90-5
• 化学式: C13H9N5O5S2
• 分子量: 379.4
• InChiKey: QFRLDZGQEZCCJZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.92±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：>10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  175
• 氢给体数：
  1
• 氢受体数：
  9

安全信息

• WGK Germany：
  2
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：US20130085128A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式I的化合物是激酶抑制剂，适用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，本发明还涉及式I的化合物的用途，特别是作为药物中的活性成分以及包含它们的药物组合物。
• SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS
  申请人：Schwink Lothar

  公开号：US20120015936A1

  公开（公告）日：2012-01-19

  The invention relates to substituted tetrahydronaphthalenes, to derivatives thereof, to physiologically acceptable salts thereof, to physiologically functional derivatives, to the production thereof, to drugs containing at least one substituted tetrahydronaphthalene according to the invention or derivative thereof, and to the use of the substituted tetrahydronaphthalenes according to the invention and to derivatives thereof as MCH antagonists.

  本发明涉及替代四氢萘的化合物，其衍生物，其生理上可接受的盐，生理功能衍生物，其生产，含有根据本发明至少一种替代四氢萘或其衍生物的药物，以及根据本发明的替代四氢萘及其衍生物作为MCH拮抗剂的用途。
• 3-[4-(PHENYLAMINOOXALYLAMINO)PHENYL]HEX-4-YNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT
  申请人：DEFOSSA Elisabeth

  公开号：US20130172248A1

  公开（公告）日：2013-07-04

  The invention relates to 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3 and R4 are each defined as specified, and to physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.

  本发明涉及3-[4-(苯胺羟草酰基氨基)苯基]己-4-炔酸及其生理相容性盐。本发明涉及式I的化合物，其中R1、R2、R3和R4分别按规定定义，并涉及其生理相容性盐。该化合物适用于治疗糖尿病等疾病。
• SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：SANOFI

  公开号：US20150133432A1

  公开（公告）日：2015-05-14

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5和R6如下所示。式I的化合物是激酶抑制剂，用于治疗与糖尿病和糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病和糖尿病视网膜病变。此外，本发明还涉及使用式I的化合物，特别是作为药物的活性成分以及包含它们的制药组合物。
• Medicament for treatment of liver cancer
  申请人：Zender Lars

  公开号：US10441577B2

  公开（公告）日：2019-10-15

  The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

  本发明提供了一种药物组合物，该组合物由索拉非尼与一种特异性激酶抑制剂组合而成，作为治疗或预防肝癌的药物。